556 related articles for article (PubMed ID: 15734729)
21. Selection of antifolate-resistant Plasmodium falciparum by sulfadoxine-pyrimethamine treatment and infectivity to Anopheles mosquitoes.
Méndez F; Herrera S; Murrain B; Gutiérrez A; Moreno LA; Manzano M; Muñoz A; Plowe CV
Am J Trop Med Hyg; 2007 Sep; 77(3):438-43. PubMed ID: 17827356
[TBL] [Abstract][Full Text] [Related]
22. Mutational 'hot-spots' in mammalian, bacterial and protozoal dihydrofolate reductases associated with antifolate resistance: sequence and structural comparison.
Volpato JP; Pelletier JN
Drug Resist Updat; 2009; 12(1-2):28-41. PubMed ID: 19272832
[TBL] [Abstract][Full Text] [Related]
23. Insights into antifolate resistance from malarial DHFR-TS structures.
Yuvaniyama J; Chitnumsub P; Kamchonwongpaisan S; Vanichtanankul J; Sirawaraporn W; Taylor P; Walkinshaw MD; Yuthavong Y
Nat Struct Biol; 2003 May; 10(5):357-65. PubMed ID: 12704428
[TBL] [Abstract][Full Text] [Related]
24. Identification of the optimal third generation antifolate against P. falciparum and P. vivax.
Hunt SY; Detering C; Varani G; Jacobus DP; Schiehser GA; Shieh HM; Nevchas I; Terpinski J; Sibley CH
Mol Biochem Parasitol; 2005 Dec; 144(2):198-205. PubMed ID: 16181688
[TBL] [Abstract][Full Text] [Related]
25. A genetically hard-wired metabolic transcriptome in Plasmodium falciparum fails to mount protective responses to lethal antifolates.
Ganesan K; Ponmee N; Jiang L; Fowble JW; White J; Kamchonwongpaisan S; Yuthavong Y; Wilairat P; Rathod PK
PLoS Pathog; 2008 Nov; 4(11):e1000214. PubMed ID: 19023412
[TBL] [Abstract][Full Text] [Related]
26. Biochemical and genetic tests for inhibitors of Leishmania pteridine pathways.
Hardy LW; Matthews W; Nare B; Beverley SM
Exp Parasitol; 1997 Nov; 87(3):157-69. PubMed ID: 9371081
[TBL] [Abstract][Full Text] [Related]
27. Malarial (Plasmodium falciparum) dihydrofolate reductase-thymidylate synthase: structural basis for antifolate resistance and development of effective inhibitors.
Yuthavong Y; Yuvaniyama J; Chitnumsub P; Vanichtanankul J; Chusacultanachai S; Tarnchompoo B; Vilaivan T; Kamchonwongpaisan S
Parasitology; 2005 Mar; 130(Pt 3):249-59. PubMed ID: 15796007
[TBL] [Abstract][Full Text] [Related]
28. Folate metabolism as a source of molecular targets for antimalarials.
Yuthavong Y; Kamchonwongpaisan S; Leartsakulpanich U; Chitnumsub P
Future Microbiol; 2006 Jun; 1(1):113-25. PubMed ID: 17661690
[TBL] [Abstract][Full Text] [Related]
29. [Drug-resistant malaria: problems with its definition and technical approaches].
Basco L; Ringwald P
Sante; 2000; 10(1):47-50. PubMed ID: 10827363
[TBL] [Abstract][Full Text] [Related]
30. Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies.
Laufer MK; Plowe CV
Drug Resist Updat; 2004; 7(4-5):279-88. PubMed ID: 15533765
[TBL] [Abstract][Full Text] [Related]
31. Biochemical aspects of drug action and resistance in malaria parasites.
Yuthavong Y; Panijpan B; Ruenwongsa P; Sirawaraporn W
Southeast Asian J Trop Med Public Health; 1985 Sep; 16(3):459-72. PubMed ID: 3913002
[TBL] [Abstract][Full Text] [Related]
32. Cancer research: from folate antagonism to molecular targets.
Bertino JR
Best Pract Res Clin Haematol; 2009 Dec; 22(4):577-82. PubMed ID: 19959110
[TBL] [Abstract][Full Text] [Related]
33. The dihydrofolate reductase-thymidylate synthetase gene in the drug resistance of malaria parasites.
Hyde JE
Pharmacol Ther; 1990; 48(1):45-59. PubMed ID: 2274577
[TBL] [Abstract][Full Text] [Related]
34. Impaired fitness of drug-resistant malaria parasites: evidence and implication on drug-deployment policies.
Babiker HA; Hastings IM; Swedberg G
Expert Rev Anti Infect Ther; 2009 Jun; 7(5):581-93. PubMed ID: 19485798
[TBL] [Abstract][Full Text] [Related]
35. Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania.
Schönfeld M; Barreto Miranda I; Schunk M; Maduhu I; Maboko L; Hoelscher M; Berens-Riha N; Kitua A; Löscher T
Malar J; 2007 Jan; 6():2. PubMed ID: 17224049
[TBL] [Abstract][Full Text] [Related]
36. Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet?
Nzila A; Ochong E; Nduati E; Gilbert K; Winstanley P; Ward S; Marsh K
Trans R Soc Trop Med Hyg; 2005 May; 99(5):341-6. PubMed ID: 15780340
[TBL] [Abstract][Full Text] [Related]
37. Resistance to sulphadrug-based antifolate therapy in malaria: are we looking in the right place?
Platteeuw JJ
Trop Med Int Health; 2006 Jun; 11(6):804-8. PubMed ID: 16772001
[TBL] [Abstract][Full Text] [Related]
38. Elucidation of sulfadoxine resistance with structural models of the bifunctional Plasmodium falciparum dihydropterin pyrophosphokinase-dihydropteroate synthase.
de Beer TA; Louw AI; Joubert F
Bioorg Med Chem; 2006 Jul; 14(13):4433-43. PubMed ID: 16517168
[TBL] [Abstract][Full Text] [Related]
39. Exploring the folate pathway in Plasmodium falciparum.
Hyde JE
Acta Trop; 2005 Jun; 94(3):191-206. PubMed ID: 15845349
[TBL] [Abstract][Full Text] [Related]
40. Molecular basis of antifolate resistance.
Assaraf YG
Cancer Metastasis Rev; 2007 Mar; 26(1):153-81. PubMed ID: 17333344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
